ROCHE HLDG LTD SPONS Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (31)

Latest Posts

About This Stock More About This Stock
3 Large-Cap Pharma Stocks To Watch Out For This New Year
Article By: Zacks Investment Research
Friday, January 5, 2018 4:35 AM EST
The year 2017 has turned out to be pretty impressive for the pharma/biotech stocks.
In this article: NVO, RHHBY, ABBV Also: AMGN
Read
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates From Novartis
Article By: Arpita Dutt
Saturday, December 30, 2017 7:49 PM EST
Key announcements in the pharma space this week include a couple of acquisition announcements and regulatory updates from Novartis.
In this article: AGN, AZN, BMY, GSK, NVS, RHHBY, MNK
Read
E The Market Before Christmas
Article By: Vivian Lewis
Sunday, December 24, 2017 12:12 PM EST
The last trading day before Christmas-to-New Year week, when markets tend to be quiet, was mainly about closing deals before 2018 and Catalonia.
In this article: BHP, BNS, DTE, EC, SLB, VOD, AZSEY, MXCHF, RHHBY, AAPL, LBTYA, PDI, BITCOMP, FCAU, INVVY
Read
Biotech Bounce “Ignyted” By Roche Deal
Article By: Rod Raynovich
Friday, December 22, 2017 3:07 PM EST
Biotech stocks escaped the doldrums today ignited by Roche (RHHBY) acquisition of Ignyta, Inc. (RXDX) for $1.7B in an all-cash transaction.
In this article: RHHBY, RXDX Also: ARRY, IBB, CELG, EXEL, SAGE, GLYC, AGIO, TSRO, EDIT, BPMC
Read
Roche Deal Seen As Boon For Other Targeted Cancer Therapy Developers
Article By: The Fly
Friday, December 22, 2017 1:20 PM EST
Roche announced a definitive agreement to fully acquire Ignyta at a price of $27 per share in an all-cash transaction valued at $1.7B on a fully diluted basis.
In this article: RHHBY Also: RXDX, LOXO, MRTX, EXEL, KPTI, SRRA
Read

PARTNER HEADLINES

Latest Tweets for $RHHBY

No tweets yet!